Entering text into the input field will update the search result below

Nevro: Harvesting An Epic Growth Opportunity

Apr. 06, 2021 3:10 AM ETNevro Corp. (NVRO) Stock9 Comments
Out of Ignorance profile picture
Out of Ignorance


  • Painful diabetic neuropathy [PDN] is a condition that affects ~30% of diabetics; there are various treatments but no cure.
  • Nevro is advancing its application to the FDA for its spinal cord stimulation treatment of PDN with a potential launch later this year.
  • Nevro is guiding for a strong recovery in 2021, which is highly sensitive to COVID-19, with the bulk of PDN growth expected in 2022.
  • There are interesting undercurrents to consider before investing in Nevro.
A man hiking beneath giant Sequoia trees.
Photo by Jordan Siemens/DigitalVision via Getty Images

Nevro (NYSE:NVRO) is one of the major participants in the spinal cord stimulation [SCS] market competing with Abbott Laboratories (ABT), Medtronic (MDT), and Boston Scientific (BSX). This article reviews its current prospects with

This article was written by

Out of Ignorance profile picture
Writing under the pseudonym "out of ignorance", I very much regard investing as a learning process. Investing failures are tuition paid. Investing successes enter the trove of lessons learned. In my Seeking Alpha articles I share my experience from decades of investing and from ~5 years of focused research on a variety of stocks, in recent years with a primary emphasis on healthcare stocks. I greatly appreciate those who take the time to share their reactions to articles, particularly those who share relevant anecdotes and experiences.

Analyst’s Disclosure: I am/we are long ABT. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

I may buy or sell shares in any stock mentioned over the next 72 hours.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (9)

charly333 profile picture
That chart sure looks broken. And fundamentally I tend to the shorts.
‘SCS is not like just popping a pill.’

Exactly right, as SCS falls right in line with similar epileptic VNS (vagus nerve stimulators) applications. There is an enormous leap that patients have to consider when going from a pill to surgery.

Thanks for the article.
Out of Ignorance profile picture
Thanks for reading and commenting. I expect that SCS will become more of a mainline treatment once a "killer app" develops for it. Perhaps PDN will become that killer app some day.
@Out of Ignorance Agreed and who knows. Anything is possible if the research and statistics are there to support it.
MachineLearning profile picture
@Out of Ignorance PDN is what they are selling and just tanked by nearly 30% after the lackluster growth numbers from it. I have said it before and will say it again. Only buy this stock if you don't mind it never making any profits from sales. Buy it for the hype of growth or buyout only. It will never be a profitable business as it is currently structured.
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!

About NVRO

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on NVRO

Related Stocks

SymbolLast Price% Chg
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.